ICU sedation, delirium & recovery
Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients
Authors' conclusion
Most critically ill Allo-HSCT recipients survive their ICU stays, including those requiring mechanical ventilation, with an overall 90-day survival rate reaching 51.8%.
Study context
- Population
- Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients admitted to 14 French ICUs, January 1, 2015–December 31, 2020
- Participants
- 1,164 recipients
- Outcome
- 90-day mortality
- Follow-up
- 90 days
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- 90-day mortality rate
- 48%
- Age > 56 years independently associated with 90-day mortality
- OR 2.0 [1.53-2.60]; P < 0.001 (95% CI, P)
- Time from Allo-HSCT to ICU admission 30–90 days
- OR 1.68 [1.17-2.40]; P = 0.005 (95% CI, P)
- Corticosteroid-refractory acute graft-versus-host disease
- OR 1.63 [1.38-1.93]; P < 0.001 (95% CI, P)
- Need for vasopressors
- OR 1.9 [1.42-2.55]; P < 0.001 (95% CI, P)
- Mechanical ventilation
- OR 3.1 [2.29-4.18]; P < 0.001 (95% CI, P)
Observational data: associations, not effects.
Further findings
ICU mortality
- ICU mortality (302 deaths)
- 26%
1-year and 3-year mortality
- 1-year mortality
- 63%
- 3-year mortality
- 70%
Mortality in patients requiring mechanical ventilation (subgroup)
- No other risk factors for mortality
- 39%
- Four associated risk factors for mortality
- 100%
Status at ICU admission
- Multiple organ dysfunction, n (%)
- 765 (66%)
- Acute respiratory failure, % (n)
- 40% (n = 461)
- SOFA score, median (IQR)
- 6 (4-8)
- Invasive mechanical ventilation, n (%)
- 438 (38%)
- RRT, n (%)
- 221 (19%)
- Vasopressors, n (%)
- 468 (41%)
Original publication
Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients. Am J Respir Crit Care Med. Published 15 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →